Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 28 September 2011
Revision date: 09-Nov-2011
Length: 32 pages
Data source: Field research
Abstract
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and cons of merging the two companies with different cultures, the value of Genentech, and the tactics of a hostile tender offer.
Teaching and learning
This item is suitable for executive education courses.Time period
The events covered by this case took place in 2008-2009.Geographical setting
Region:
World/global
Countries:
Switzerland; United States
Featured companies
Roche Group
Industry:
Biotechnology; Pharmaceuticals
Genentech
Industry:
Biotechnology; Pharmaceuticals
Featured protagonist
- Franz Humer (male), CEO
About
Abstract
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and cons of merging the two companies with different cultures, the value of Genentech, and the tactics of a hostile tender offer.
Teaching and learning
This item is suitable for executive education courses.Settings
Time period
The events covered by this case took place in 2008-2009.Geographical setting
Region:
World/global
Countries:
Switzerland; United States
Featured companies
Roche Group
Industry:
Biotechnology; Pharmaceuticals
Genentech
Industry:
Biotechnology; Pharmaceuticals
Featured protagonist
- Franz Humer (male), CEO